Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients

Targeted therapy, especially the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPis), has improved the outcome of patients with ovarian cancer. However, most high-grade serous ovarian cancer (HGSOC) patients have wild-type BRCA1/2, and it is necessary to disclose more po...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2022-10, Vol.238, p.154074-154074, Article 154074
Main Authors: Tao, Junyan, Sun, Dantong, Zhou, Hai, Zhu, Jingjuan, Zhang, Xiaochun, Hou, Helei
Format: Article
Language:English
Subjects:
HGSOC
Molecularly targeted therapy
Next-generation sequencing
Personalized therapy
Precision medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3
cites cdi_FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3
container_end_page 154074
container_issue
container_start_page 154074
container_title Pathology, research and practice
container_volume 238
creator Tao, Junyan
Sun, Dantong
Zhou, Hai
Zhu, Jingjuan
Zhang, Xiaochun
Hou, Helei
description Targeted therapy, especially the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPis), has improved the outcome of patients with ovarian cancer. However, most high-grade serous ovarian cancer (HGSOC) patients have wild-type BRCA1/2, and it is necessary to disclose more potential novel targets for other available targeted drugs. So, detection of genetic alterations beyond BRCA1/2 is critical to screen HGSOC patients for personalized therapy. In this study, a broad, hybrid capture-based next-generation sequencing (NGS) assay was used to identify actionable genetic alterations from HGSOC cancer tissues. Sixty-eight patients with HGSOC were enrolled, including 6 International Federation of Gynecology and Obstetrics (FIGO) stage I, 15 stage II, 37 stage III and 10 stage IV patients. All patients signed informed consent forms. Potentially actionable genetic alterations, including base substitutions, indels, copy number alterations, and gene fusions, were identified using targeted NGS. In our study, 14.7% (10/68) of the tumors harbored actionable genetic alterations in patients with BRCA1. A total of 25.0% (17/68) of patients without BRCA1 mutations harbored other actionable genetic alterations, such as homologous recombination repair (HRR) pathway-related genes (ATM, CDK12, FANCA, and FANCD2), PI3K/AKT/mTOR pathway genes (NF1, FBXW7, PIK3CA, PTEN, TSC1, and TSC2), and some other genes (ARID1A, FGFR1, KRAS, and NRAS). Furthermore, some patients harboring ARID1A or NF1 actionable genetic alterations showed good clinical efficacy to immune checkpoint inhibitors (ICIs) and everolimus, respectively. Our research indicates that 39.7% (27/68) of patients with HGSOC harbored at least one actionable genetic alteration. 25.0% (17/68) of patients had somatic mutations or copy number variations beyond BRCA1 mutations and might be treated with off-label therapy or to be allocated into clinical trial. NGS assays of HGSOC patients are necessary to screen actionable genetic alterations to guide personalized and precise treatment.
doi_str_mv 10.1016/j.prp.2022.154074
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2705399841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033822003181</els_id><sourcerecordid>2705399841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWD9-gLccvWydSdL9wJMUtULRg95Dmp2tKdvsmqRF_70p9exphuF9Bp6XsRuEKQKWd5vpGMapACGmOFNQqRM2wRLrAkqJp2wCUqkCpKzP2UWMGwCoQOGE2Vf6TsWaPAWT3OB5pK8deev8mruWfHKdo8jHIR1203M_7Knn6TPnR9olZ3kyYU0pcuf5_NN5isQXz-9vcz7mj5mKV-ysM32k6795yT6eHj_mi2L59vwyf1gWVpSQCio729nG2qaVUK8qqSRWKzSiM0YgZYMZtm3ZldCISigiXFVKNdi1NQi7kpfs9vh2DEN2iElvXbTU98bTsItaVDCTTVMrzFE8Rm0YYgzU6TG4rQk_GkEf-tSbfBn1oU997DMz90eGssLeUdDRZj1LrQtkk24H9w_9CwEtf1k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2705399841</pqid></control><display><type>article</type><title>Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients</title><source>ScienceDirect Journals</source><creator>Tao, Junyan ; Sun, Dantong ; Zhou, Hai ; Zhu, Jingjuan ; Zhang, Xiaochun ; Hou, Helei</creator><creatorcontrib>Tao, Junyan ; Sun, Dantong ; Zhou, Hai ; Zhu, Jingjuan ; Zhang, Xiaochun ; Hou, Helei</creatorcontrib><description>Targeted therapy, especially the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPis), has improved the outcome of patients with ovarian cancer. However, most high-grade serous ovarian cancer (HGSOC) patients have wild-type BRCA1/2, and it is necessary to disclose more potential novel targets for other available targeted drugs. So, detection of genetic alterations beyond BRCA1/2 is critical to screen HGSOC patients for personalized therapy. In this study, a broad, hybrid capture-based next-generation sequencing (NGS) assay was used to identify actionable genetic alterations from HGSOC cancer tissues. Sixty-eight patients with HGSOC were enrolled, including 6 International Federation of Gynecology and Obstetrics (FIGO) stage I, 15 stage II, 37 stage III and 10 stage IV patients. All patients signed informed consent forms. Potentially actionable genetic alterations, including base substitutions, indels, copy number alterations, and gene fusions, were identified using targeted NGS. In our study, 14.7% (10/68) of the tumors harbored actionable genetic alterations in patients with BRCA1. A total of 25.0% (17/68) of patients without BRCA1 mutations harbored other actionable genetic alterations, such as homologous recombination repair (HRR) pathway-related genes (ATM, CDK12, FANCA, and FANCD2), PI3K/AKT/mTOR pathway genes (NF1, FBXW7, PIK3CA, PTEN, TSC1, and TSC2), and some other genes (ARID1A, FGFR1, KRAS, and NRAS). Furthermore, some patients harboring ARID1A or NF1 actionable genetic alterations showed good clinical efficacy to immune checkpoint inhibitors (ICIs) and everolimus, respectively. Our research indicates that 39.7% (27/68) of patients with HGSOC harbored at least one actionable genetic alteration. 25.0% (17/68) of patients had somatic mutations or copy number variations beyond BRCA1 mutations and might be treated with off-label therapy or to be allocated into clinical trial. NGS assays of HGSOC patients are necessary to screen actionable genetic alterations to guide personalized and precise treatment.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/j.prp.2022.154074</identifier><language>eng</language><publisher>Elsevier GmbH</publisher><subject>HGSOC ; Molecularly targeted therapy ; Next-generation sequencing ; Personalized therapy ; Precision medicine</subject><ispartof>Pathology, research and practice, 2022-10, Vol.238, p.154074-154074, Article 154074</ispartof><rights>2022 Elsevier GmbH</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3</citedby><cites>FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Tao, Junyan</creatorcontrib><creatorcontrib>Sun, Dantong</creatorcontrib><creatorcontrib>Zhou, Hai</creatorcontrib><creatorcontrib>Zhu, Jingjuan</creatorcontrib><creatorcontrib>Zhang, Xiaochun</creatorcontrib><creatorcontrib>Hou, Helei</creatorcontrib><title>Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients</title><title>Pathology, research and practice</title><description>Targeted therapy, especially the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPis), has improved the outcome of patients with ovarian cancer. However, most high-grade serous ovarian cancer (HGSOC) patients have wild-type BRCA1/2, and it is necessary to disclose more potential novel targets for other available targeted drugs. So, detection of genetic alterations beyond BRCA1/2 is critical to screen HGSOC patients for personalized therapy. In this study, a broad, hybrid capture-based next-generation sequencing (NGS) assay was used to identify actionable genetic alterations from HGSOC cancer tissues. Sixty-eight patients with HGSOC were enrolled, including 6 International Federation of Gynecology and Obstetrics (FIGO) stage I, 15 stage II, 37 stage III and 10 stage IV patients. All patients signed informed consent forms. Potentially actionable genetic alterations, including base substitutions, indels, copy number alterations, and gene fusions, were identified using targeted NGS. In our study, 14.7% (10/68) of the tumors harbored actionable genetic alterations in patients with BRCA1. A total of 25.0% (17/68) of patients without BRCA1 mutations harbored other actionable genetic alterations, such as homologous recombination repair (HRR) pathway-related genes (ATM, CDK12, FANCA, and FANCD2), PI3K/AKT/mTOR pathway genes (NF1, FBXW7, PIK3CA, PTEN, TSC1, and TSC2), and some other genes (ARID1A, FGFR1, KRAS, and NRAS). Furthermore, some patients harboring ARID1A or NF1 actionable genetic alterations showed good clinical efficacy to immune checkpoint inhibitors (ICIs) and everolimus, respectively. Our research indicates that 39.7% (27/68) of patients with HGSOC harbored at least one actionable genetic alteration. 25.0% (17/68) of patients had somatic mutations or copy number variations beyond BRCA1 mutations and might be treated with off-label therapy or to be allocated into clinical trial. NGS assays of HGSOC patients are necessary to screen actionable genetic alterations to guide personalized and precise treatment.</description><subject>HGSOC</subject><subject>Molecularly targeted therapy</subject><subject>Next-generation sequencing</subject><subject>Personalized therapy</subject><subject>Precision medicine</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWD9-gLccvWydSdL9wJMUtULRg95Dmp2tKdvsmqRF_70p9exphuF9Bp6XsRuEKQKWd5vpGMapACGmOFNQqRM2wRLrAkqJp2wCUqkCpKzP2UWMGwCoQOGE2Vf6TsWaPAWT3OB5pK8deev8mruWfHKdo8jHIR1203M_7Knn6TPnR9olZ3kyYU0pcuf5_NN5isQXz-9vcz7mj5mKV-ysM32k6795yT6eHj_mi2L59vwyf1gWVpSQCio729nG2qaVUK8qqSRWKzSiM0YgZYMZtm3ZldCISigiXFVKNdi1NQi7kpfs9vh2DEN2iElvXbTU98bTsItaVDCTTVMrzFE8Rm0YYgzU6TG4rQk_GkEf-tSbfBn1oU997DMz90eGssLeUdDRZj1LrQtkk24H9w_9CwEtf1k</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Tao, Junyan</creator><creator>Sun, Dantong</creator><creator>Zhou, Hai</creator><creator>Zhu, Jingjuan</creator><creator>Zhang, Xiaochun</creator><creator>Hou, Helei</creator><general>Elsevier GmbH</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202210</creationdate><title>Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients</title><author>Tao, Junyan ; Sun, Dantong ; Zhou, Hai ; Zhu, Jingjuan ; Zhang, Xiaochun ; Hou, Helei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>HGSOC</topic><topic>Molecularly targeted therapy</topic><topic>Next-generation sequencing</topic><topic>Personalized therapy</topic><topic>Precision medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tao, Junyan</creatorcontrib><creatorcontrib>Sun, Dantong</creatorcontrib><creatorcontrib>Zhou, Hai</creatorcontrib><creatorcontrib>Zhu, Jingjuan</creatorcontrib><creatorcontrib>Zhang, Xiaochun</creatorcontrib><creatorcontrib>Hou, Helei</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tao, Junyan</au><au>Sun, Dantong</au><au>Zhou, Hai</au><au>Zhu, Jingjuan</au><au>Zhang, Xiaochun</au><au>Hou, Helei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients</atitle><jtitle>Pathology, research and practice</jtitle><date>2022-10</date><risdate>2022</risdate><volume>238</volume><spage>154074</spage><epage>154074</epage><pages>154074-154074</pages><artnum>154074</artnum><issn>0344-0338</issn><eissn>1618-0631</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Targeted therapy, especially the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPis), has improved the outcome of patients with ovarian cancer. However, most high-grade serous ovarian cancer (HGSOC) patients have wild-type BRCA1/2, and it is necessary to disclose more potential novel targets for other available targeted drugs. So, detection of genetic alterations beyond BRCA1/2 is critical to screen HGSOC patients for personalized therapy. In this study, a broad, hybrid capture-based next-generation sequencing (NGS) assay was used to identify actionable genetic alterations from HGSOC cancer tissues. Sixty-eight patients with HGSOC were enrolled, including 6 International Federation of Gynecology and Obstetrics (FIGO) stage I, 15 stage II, 37 stage III and 10 stage IV patients. All patients signed informed consent forms. Potentially actionable genetic alterations, including base substitutions, indels, copy number alterations, and gene fusions, were identified using targeted NGS. In our study, 14.7% (10/68) of the tumors harbored actionable genetic alterations in patients with BRCA1. A total of 25.0% (17/68) of patients without BRCA1 mutations harbored other actionable genetic alterations, such as homologous recombination repair (HRR) pathway-related genes (ATM, CDK12, FANCA, and FANCD2), PI3K/AKT/mTOR pathway genes (NF1, FBXW7, PIK3CA, PTEN, TSC1, and TSC2), and some other genes (ARID1A, FGFR1, KRAS, and NRAS). Furthermore, some patients harboring ARID1A or NF1 actionable genetic alterations showed good clinical efficacy to immune checkpoint inhibitors (ICIs) and everolimus, respectively. Our research indicates that 39.7% (27/68) of patients with HGSOC harbored at least one actionable genetic alteration. 25.0% (17/68) of patients had somatic mutations or copy number variations beyond BRCA1 mutations and might be treated with off-label therapy or to be allocated into clinical trial. NGS assays of HGSOC patients are necessary to screen actionable genetic alterations to guide personalized and precise treatment.</abstract><pub>Elsevier GmbH</pub><doi>10.1016/j.prp.2022.154074</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-0338
ispartof Pathology, research and practice, 2022-10, Vol.238, p.154074-154074, Article 154074
issn 0344-0338
1618-0631
language eng
recordid cdi_proquest_miscellaneous_2705399841
source ScienceDirect Journals
subjects HGSOC
Molecularly targeted therapy
Next-generation sequencing
Personalized therapy
Precision medicine
title Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-30T18%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Next-generation%20sequencing%20identifies%20potential%20novel%20therapeutic%20targets%20in%20Chinese%20HGSOC%20patients&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=Tao,%20Junyan&rft.date=2022-10&rft.volume=238&rft.spage=154074&rft.epage=154074&rft.pages=154074-154074&rft.artnum=154074&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/j.prp.2022.154074&rft_dat=%3Cproquest_cross%3E2705399841%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c260t-e6fcfc9cc9d308b734317b1a2faa21e03451dd6f6092724ee1b74491fd802cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2705399841&rft_id=info:pmid/&rfr_iscdi=true